Fri Aug 4 16:55:15 2006
Robust hepatitis C virus infection in vitro
Zhong J, Gastaminza P, Cheng GF, et al.
PNAS 102 (26): 9294-9299 JUN 28 2005
and citing papers
stopwords, and 2-character and smaller words are excluded, Word count: 611, All words count: 910
Grand TLCS: 121, Grand TGCS: 212View: Overview | Sorted by word. |
Page 1 of 2: [ 1 2 ]
# | Word | Pubs | TLCS | TGCS
|
---|
1 | ACHILLES | 1 | 0 | 0
|
2 | ACTION | 1 | 3 | 15
|
3 | ACTIVATION | 3 | 4 | 4
|
4 | ACTIVE | 1 | 0 | 0
|
5 | ACTIVITIES | 1 | 0 | 0
|
6 | ACTIVITY | 2 | 0 | 0
|
7 | ADAPTIVE | 1 | 0 | 0
|
8 | ADAPTOR | 1 | 7 | 41
|
9 | ADVANCES | 1 | 0 | 1
|
10 | ALPHA | 1 | 0 | 0
|
11 | ALPHA-GLUCOSIDASE | 1 | 0 | 0
|
12 | ANALYSES | 1 | 0 | 0
|
13 | ANALYSIS | 3 | 2 | 4
|
14 | ANTI-HCV | 1 | 0 | 0
|
15 | ANTI-HEPATITIS | 1 | 1 | 1
|
16 | ANTIBODIES | 1 | 0 | 0
|
17 | ANTIBODY | 1 | 0 | 0
|
18 | ANTIVIRAL | 6 | 7 | 42
|
19 | APOB-CONTAINING | 1 | 0 | 0
|
20 | APOLIPOPROTEIN | 1 | 0 | 0
|
21 | APOPTOSIS | 1 | 1 | 2
|
22 | APPLIED | 1 | 0 | 0
|
23 | APPROACH | 1 | 0 | 0
|
24 | ASSAY | 2 | 0 | 0
|
25 | ASSEMBLY | 1 | 1 | 2
|
26 | BASIC | 1 | 0 | 0
|
27 | BILIARY | 1 | 0 | 0
|
28 | BINDING | 2 | 0 | 0
|
29 | BIOLOGICAL | 2 | 0 | 1
|
30 | BREAKTHROUGH | 1 | 0 | 0
|
# | Word | Pubs | TLCS | TGCS
|
---|
31 | BROADLY | 1 | 0 | 0
|
32 | CAPTURING | 1 | 0 | 0
|
33 | CARCINOMA | 1 | 0 | 0
|
34 | CARDIF | 1 | 7 | 41
|
35 | CDNA-TRANSFECTED | 1 | 2 | 2
|
36 | CELL | 9 | 7 | 8
|
37 | CELL-BASED | 1 | 0 | 1
|
38 | CELL-CELL | 1 | 0 | 0
|
39 | CELLS | 7 | 4 | 4
|
40 | CHARACTERIZATION | 4 | 0 | 0
|
41 | CHIMERAS | 1 | 0 | 0
|
42 | CIRCLE | 1 | 1 | 2
|
43 | CLA | 1 | 0 | 0
|
44 | CLATHRIN-MEDIATED | 1 | 0 | 0
|
45 | CLEAVAGE | 1 | 0 | 0
|
46 | CLINICAL | 1 | 0 | 1
|
47 | COMBINATION | 1 | 0 | 0
|
48 | COMPLEX | 1 | 2 | 4
|
49 | CONCOMITANT | 1 | 1 | 2
|
50 | CONFLUENCE-BASED | 1 | 0 | 1
|
51 | CONSTRUCTION | 1 | 0 | 0
|
52 | CONTROL | 1 | 1 | 1
|
53 | CORE-RNA | 1 | 0 | 0
|
54 | COUNTERS | 1 | 0 | 2
|
55 | CULTURE | 5 | 5 | 6
|
56 | CULTURE-GROWN | 1 | 2 | 2
|
57 | CULTURED | 1 | 1 | 1
|
58 | CULTURES | 1 | 0 | 0
|
59 | CYCLOSPORIN | 1 | 0 | 0
|
60 | CYCLOSPORINE | 1 | 0 | 0
|
# | Word | Pubs | TLCS | TGCS
|
---|
61 | CYTOSKELETON | 1 | 0 | 0
|
62 | DC-SIGN | 1 | 0 | 0
|
63 | DC-SIGNR | 1 | 0 | 0
|
64 | DEBIO | 1 | 0 | 0
|
65 | DEFENCE | 1 | 3 | 19
|
66 | DEFINED | 1 | 0 | 0
|
67 | DELETION | 1 | 0 | 0
|
68 | DENSITY | 1 | 0 | 0
|
69 | DEPENDS | 1 | 0 | 0
|
70 | DETECTION | 1 | 1 | 1
|
71 | DEVELOPMENT | 2 | 0 | 1
|
72 | DIFFERENCE | 1 | 3 | 3
|
73 | DIFFERENT | 2 | 0 | 0
|
74 | DIHYDROXY-4-CARBOXYPYRIMIDINES | 1 | 0 | 0
|
75 | DIMERIZATION | 1 | 0 | 0
|
76 | DIRECT | 1 | 0 | 0
|
77 | DISCOVERY | 1 | 0 | 0
|
78 | DISORDERS | 1 | 0 | 0
|
79 | DISPENSABLE | 1 | 0 | 0
|
80 | DISTINCT | 2 | 0 | 0
|
81 | DIVERSE | 1 | 0 | 0
|
82 | DOMAINS | 1 | 0 | 0
|
83 | DRUG | 1 | 0 | 1
|
84 | DSRNA-INDUCED | 1 | 0 | 0
|
85 | EARLY | 1 | 0 | 0
|
86 | EFFECT | 3 | 0 | 1
|
87 | EFFECTS | 2 | 1 | 1
|
88 | EFFICIENT | 1 | 3 | 3
|
89 | EFFICIENTLY | 1 | 1 | 1
|
90 | EMPIRICISM | 1 | 0 | 0
|
# | Word | Pubs | TLCS | TGCS
|
---|
91 | ENDOCYTOSIS | 1 | 0 | 0
|
92 | ENDOTHELIUM | 1 | 0 | 0
|
93 | ENGAGEMENT | 1 | 0 | 0
|
94 | ENHANCES | 1 | 0 | 0
|
95 | ENTRY | 6 | 5 | 5
|
96 | ENVELOPE | 1 | 0 | 0
|
97 | EPITOPE | 1 | 0 | 0
|
98 | ERADICATION | 1 | 0 | 0
|
99 | ESCAPE | 1 | 0 | 0
|
100 | EVASION | 1 | 3 | 19
|
101 | EXHIBITS | 1 | 0 | 0
|
102 | EXPRESSION | 3 | 0 | 1
|
103 | FACE | 1 | 0 | 1
|
104 | FEATURES | 1 | 1 | 1
|
105 | FULL | 1 | 1 | 2
|
106 | FULLY | 1 | 0 | 0
|
107 | FUNCTION | 2 | 8 | 15
|
108 | FUNCTIONAL | 2 | 1 | 2
|
109 | FUNCTIONS | 1 | 0 | 0
|
110 | FUSION | 2 | 3 | 3
|
111 | FUTURE | 1 | 0 | 1
|
112 | GENERATED | 1 | 0 | 0
|
113 | GENERATION | 1 | 0 | 0
|
114 | GENOME | 2 | 8 | 15
|
115 | GENOTYPE | 3 | 1 | 2
|
116 | GLYCOPROTEINS | 2 | 4 | 5
|
117 | GROW | 1 | 0 | 0
|
118 | GROWTH | 1 | 0 | 1
|
119 | HAIRPIN | 1 | 0 | 0
|
120 | HCV | 6 | 2 | 3
|
# | Word | Pubs | TLCS | TGCS
|
---|
121 | HEEL | 1 | 0 | 0
|
122 | HELICASE | 1 | 0 | 0
|
123 | HELICASES | 1 | 0 | 0
|
124 | HEPATITIS | 58 | 120 | 210
|
125 | HEPATOCELLULAR | 1 | 0 | 0
|
126 | HEPATOCYTES | 1 | 0 | 0
|
127 | HEPATOMA | 3 | 4 | 4
|
128 | HIGH | 1 | 0 | 0
|
129 | HIGHLY | 1 | 0 | 1
|
130 | HOME-GROWN | 1 | 0 | 0
|
131 | HORSE | 1 | 0 | 0
|
132 | HOST | 3 | 6 | 22
|
133 | HUMAN | 6 | 4 | 4
|
134 | HUTCHINSON | 1 | 1 | 1
|
135 | IDENTIFY | 1 | 0 | 0
|
136 | IFN-BETA | 1 | 1 | 1
|
137 | IMMORTALIZED | 1 | 0 | 0
|
138 | IMMUNE | 1 | 0 | 0
|
139 | IMMUNITY | 1 | 0 | 2
|
140 | INCORPORATION | 1 | 1 | 2
|
141 | INDEPENDENT | 1 | 0 | 0
|
142 | INDUCED | 2 | 0 | 0
|
143 | INFECTION | 4 | 72 | 72
|
144 | INFECTIOUS | 8 | 7 | 9
|
145 | INHIBIT | 1 | 0 | 0
|
146 | INHIBITION | 2 | 0 | 1
|
147 | INHIBITOR | 4 | 0 | 1
|
148 | INHIBITORS | 2 | 0 | 0
|
149 | INHIBITS | 3 | 2 | 3
|
150 | INNATE | 2 | 0 | 2
|
# | Word | Pubs | TLCS | TGCS
|
---|
151 | INSERTION | 1 | 0 | 0
|
152 | INSIGHTS | 1 | 0 | 0
|
153 | INTERACTION | 2 | 0 | 0
|
154 | INTERACTIONS | 2 | 3 | 9
|
155 | INTERFERENCE-MEDIATED | 1 | 0 | 0
|
156 | INTERFERING | 1 | 0 | 2
|
157 | INTERFERON | 4 | 4 | 16
|
158 | INTERFERON-SENSITIVE | 1 | 0 | 1
|
159 | INTERFERONS | 1 | 0 | 2
|
160 | INTERGENOTYPIC | 1 | 0 | 0
|
161 | INTERNAL | 1 | 0 | 0
|
162 | INTRACELLULAR | 2 | 3 | 19
|
163 | INTRACELLULARLY | 1 | 1 | 2
|
164 | INTRAGENOTYPIC | 1 | 0 | 0
|
165 | LIPOPROTEIN | 2 | 1 | 1
|
166 | LIPOPROTEINS | 2 | 0 | 0
|
167 | LIPOSOMES | 1 | 3 | 3
|
168 | LIVER | 2 | 0 | 0
|
169 | LOCALIZATION | 1 | 1 | 1
|
170 | LOW | 1 | 3 | 3
|
171 | LOW-DENSITY | 1 | 1 | 1
|
172 | LOW-PH-TRIGGERED | 1 | 4 | 4
|
173 | LUCIFERASE | 2 | 0 | 0
|
174 | MATURATION | 1 | 0 | 0
|
175 | MEASUREMENT | 1 | 0 | 0
|
176 | MECHANISM | 2 | 3 | 16
|
177 | MECHANISM-BASED | 1 | 0 | 0
|
178 | MECHANISMS | 1 | 0 | 0
|
179 | MEDIATE | 2 | 3 | 3
|
180 | MEDIATED | 1 | 0 | 0
|
# | Word | Pubs | TLCS | TGCS
|
---|
181 | MEMBRANE | 1 | 3 | 3
|
182 | MEMBRANES | 1 | 0 | 0
|
183 | MENACE | 1 | 0 | 0
|
184 | MILESTONE | 1 | 0 | 0
|
185 | MODELING | 1 | 0 | 0
|
186 | MODELS | 1 | 0 | 1
|
187 | MODULATES | 1 | 0 | 0
|
188 | MOLECULAR | 2 | 1 | 1
|
189 | MONOCLONAL | 1 | 0 | 0
|
190 | MORPHOGENESIS | 1 | 0 | 0
|
191 | MOVE | 1 | 0 | 0
|
192 | MUTAGENESIS | 1 | 0 | 0
|
193 | NATURAL | 1 | 0 | 0
|
194 | NEUTRALIZING | 1 | 0 | 0
|
195 | NEW | 1 | 0 | 0
|
196 | NON-IMMUNOSUPPRESSIVE | 1 | 0 | 0
|
197 | NON-STRUCTURAL | 1 | 0 | 0
|
198 | NONSTRUCTURAL | 1 | 0 | 0
|
199 | NOVEL | 2 | 0 | 1
|
200 | NS34A | 1 | 0 | 0
|
Page 1 of 2: [ 1 2 ]